There’s an important editorial in the LA Times today about drug-resistant tuberculosis.
A couple of excerpts:
“A new survey by the World Health Organization shows that drug-resistant tuberculosis is even more widespread than had been feared — on average, it’s present in 5% of new TB cases. That’s 500,000 drug-resistant cases a year. If most Americans aren’t concerned by this, it’s because they don’t yet understand that drug-resistant tuberculosis is no longer a disease that threatens mainly HIV and AIDS patients and the Third World poor. It threatens us all. Worldwide, only 8% of TB cases occur in HIV/AIDS patients…
Even after the panic last year caused by Andrew Speaker, the jet-setting honeymooner found to have MDR TB, funding to stop the disease has lagged. The WHO, which gets its money from United Nations member states, estimates it needs $4.8 billion for global TB control. But despite increases in funding from the U.S., Britain and private donors, it still faces a $2.5-billion shortfall.
You can read the full piece here.
They say timing is everything. Fewer than 24 hours after my colleague David Molyneux’s call to action for increased attention to neglected tropical disease (NTD) control appeared on this blog, President Bush has unveiled a $350 million commitment to fight NTDs in Africa, Asia, and Latin America over the next five years.
This commitment represents a historic step forward in the US’s global health strategy, and a major victory for the NTD advocacy movement. I applaud President Bush for taking leadership on this issue and encouraging other G-8 members, as well as public and private partners and philanthropic foundations, to follow suit.
There is no doubt that the integrated control of NTDs (providing treatment for up to seven of the most common of these infections in one package) will have a rapid and long-lasting impact on almost every facet of life for the billions who have long suffered these debilitating and disabling infections in silence. Together with other effective health and sanitation strategies, NTD control has the potential to unlock economic and educational growth (not to mention improvements in physical and mental well-being) at never-before-seen levels throughout the developing world.
This is truly a cause for great hope. The President’s funding commitment, together with money from Bill and Melinda Gates and other partners such as Geneva Global, will cover almost half of the estimated NTD funding gap over the next seven years. If President Bush’s plea to other donors is successful, perhaps we will after all consign these diseases to history.
For more information on NTDs and to join the fight, visit the Global Network for Neglected Tropical Diseases.
-Dr. Peter Hotez is President of the Sabin Vaccine Institute and Executive Director of the Global Network for Neglected Tropical Diseases, based in Washington, DC
The rhetoric surrounding President Bush’s tour of Africa has certainly been inspirational, but is marked by a common and unfortunate omission. Amid a sea of hopeful images of economic growth, educational opportunity, and life-saving healthcare, the President – like so many other global leaders these days– has displayed an inability to recognize perhaps the most important background factor linking health, wealth, and education in the developing world. The factor I am referring to is the scourge of the neglected tropical diseases (NTDs), a hidden pandemic of the world’s poorest.
Though not killers on the scale of HIV/AIDS and malaria, the NTDs – a group of infections with names like ‘schistosomiasis,’ ‘onchocerciasis,’ and ‘lymphatic filariasis’ that are a mouthful even for those of us who have made a career of fighting them – cause more disability and premature death in Africa than either malaria or tuberculosis, according to the World Health Organization. As a group, the NTDs are the most common infections of the world’s at least one billion poorest inhabitants, affecting 500 million in Africa (compared to 30 million for HIV). Simply put, no progress can be made in development without addressing these infections as well as the “big three” (HIV/AIDS, tuberculosis, and malaria) which so preoccupy politicians.
Even if you have traveled in the countries hardest hit by NTDs, you may not be familiar with them. They are hidden infections that thrive in the poorest rural and urban populations, often causing grotesquely swollen limbs, distended bellies full of worms, blindness, and mental retardation, all of which lead to severe social stigmatization. They leave adults unable to work, keep kids out of school, add to rates of infant death and low birth weight, and can speed up transmission of the HIV virus, all at alarming rates.
There is good news, however. A package of medications to treat seven of the most common NTDs is available for only 50 cents per person per year – an almost negligible price compared to treatment costs for other major infectious diseases (for example, $400 – 1200 per year to treat a case of HIV). Given this low cost and the hugely positive impacts of treatment, providing medication for NTDs is one of the single most cost-effective investments we can make with our international aid dollars.
While the President’s commitment to African health and development is admirable, we must be careful not to focus solely on the “big three” to the exclusion of other equally devastating diseases. Control of NTDs is within our grasp, and if we truly wish to invest in the future of African development, we must take action now.
For more information on NTDs or to join the fight, please visit the Global Network for Neglected Tropical Diseases.
-Professor David Molyneux, Director of the Lymphatic Filariasis Support Centre based at the Liverpool School of Tropical Medicine and current President of the Royal Society of Tropical Medicine and Hygiene
